[Federal Register: March 5, 2003 (Volume 68, Number 43)]
[Notices]
[Page 10483-10484]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr05mr03-68]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Vaccines and Related Biological Products Advisory Committee;
Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Vaccines and Related Biological Products
Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on March 18, 2003, from
10:30 a.m. to 12:45 p.m.
Location: Food and Drug Administration, 5515 Security Lane,
conference room A on the 11th floor, suite 1113, Rockville, MD. This
meeting will be held by a telephone conference call. The public is
welcome to attend the open portion of the meeting at the location in
the first sentence of this paragraph. A speaker phone will be provided
at the specified location.
Contact Person: Jody G. Sachs or Denise H. Royster, Food and Drug
Administration, Center for Biologics Evaluation and Research (HFM-71),
301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-
8138 (301-443-0572 in the Washington, DC area), code 12391. Please call
the Information Line for up-to-date information on this meeting.
Agenda: The committee will review and discuss the selection of
strains to be included in the influenza virus vaccine for the 2003-2004
season.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by March 12,
2003. Oral presentations from the public will be scheduled between
approximately 11:30 a.m. to 12:30 p.m. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before March 12, 2003,
and submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and
[[Page 10484]]
an indication of the approximate time requested to make their
presentation.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Jody G. Sachs or
Denise H. Royster at least 7 days in advance of the meeting.
FDA regrets that it was unable to publish this notice 15 days prior
to the March 18, 2003, Vaccines and Related Biological Products
Advisory Committee meeting. Because the agency believes there is some
urgency to bring this issue to public discussion and qualified members
of the Vaccines and Related Biological Products Advisory Committee were
available at this time, the Commissioner of Food and Drugs concluded
that it was in the public interest to hold this meeting even if there
was not sufficient time for the customary 15-day public notice.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: February 26, 2003.
William K. Hubbard,
Associate Commissioner for Policy and Planning.
[FR Doc. 03-5075 Filed 3-4-03; 8:45 am]
BILLING CODE 4160-01-S